Riad Salem, MD, MBA

Year in Review in Y-90 Radioembolization: Primary Liver Cancer

02/05/2022

CIO 2022-33 Atezolizumab + Bevacizumab vs Sorafenib in HCC Patients With Prior Locoregional Therapy: IMbrave150 Exploratory Data

BEST POSTER WINNER Late-breaking abstract / Here, we report post hoc exploratory results of atezo + bev vs sorafenib (sor) in pts who had prior LRT using updated IMbrave150 data with 12 m...

Michel P. Ducreux , MD, PhD;

Sairy Hernandez ;

Amit G. Singal ;

Wendy Verret ;

Allan Nicholas , MD, FACC;

Riad Salem , MD, MBA;

Richard S. Finn ;

Peter R. Galle , MD, PhD;

Andrew Zhu ;

Philippe Merle ;

10/17/2022

HCC: 2022 Year in Review

Riad Salem, MD, MBA presents notable studies from 2022 at the Symposium on Clinical Interventional Oncology.

Riad Salem , MD, MBA;

01/01/2023

CIO 2022-3 Updated Clinical and Dosimetric Recommendations for Yttrium-90 Glass Microspheres in Hepatocellular Carcinoma

Purpose: The TheraSphere Global Dosimetry Steering Committee (DSC) reconvened to update the clinical and dosimetric recommendations for the treatment of unresectable hepatocellular carcin...

Siddharth A. Padia , MD;

S. Cheenu Kappadath , PhD;

Riad Salem , MD, MBA;

Bruno Sangro , MD, PhD;

Edward Kim , MD;

Daniel Sze , MD, PhD;

Marnix Lam ;

Carlo Chiesa ;

Paul Haste ;

Beau Toskich ;

Kirk Fowers ;

Joseph M. Herman ;

Thomas Leung ;

Etienne Garin ;

10/18/2022

Evolution of Dosimetry Using Y-90 Glass Microspheres

12/07/2020

Riad Salem , MD, MBA;

Robert J. Lewandowski , MD, FSIR;

Shamar Young , MD;

Juan Gimenez , MD;

12/07/2020

IO Learning

Dose Matters

Nora Tabori, MD, Edward Kim, MD, and Riad Salem, MD present current thoughts on Y-90 dosimetry based on the EPOCH trial.

Edward S. Kim , MD, FACP, MBA;

Nora Tabori , MD;

Riad Salem , MD, MBA;

02/16/2022

Streamlining Y90: Is It Possible to Eliminate the Tc-MAA Study?

Riad Salem , MD, MBA;

11/13/2019

Evolution of Dosimetry Using Y-90 Glass Microspheres

Evolution of Dosimetry Using Y-90 Glass Microspheres presentation at CIO October 2020.

Shamar Young , MD;

Juan Gimenez , MD;

Riad Salem , MD, MBA;

Robert J. Lewandowski , MD, FSIR;

07/29/2021

Contemporary Imaging Endpoints with Locoregional Therapies

Riad Salem, MD, discusses the modified RECIST criteria and the evolution in the assessment of patient response after localized treatment of hepatocellular carcinoma.

Riad Salem , MD, MBA;

11/12/2019

Bringing it All Together: Liver Tumor Board

David M. Liu , MD, FRCPC, FSIR;

Michael Chuong , MD;

Santiago Aparo , MD, MS;

Karen T. Brown , MD, FSIR;

Horacio Asbun , MD;

Riad Salem , MD, MBA;

11/12/2019